Invivyd, Inc. (NASDAQ:IVVD) Short Interest Update

Invivyd, Inc. (NASDAQ:IVVD) was the recipient of a large decline in short interest during the month of November. As of November 15th, there was short interest totalling 6,740,000 shares, a decline of 18.5% from the October 31st total of 8,270,000 shares. Based on an average daily volume of 529,200 shares, the days-to-cover ratio is presently 12.7 days. Currently, 9.2% of the company’s stock are short sold.

Invivyd Price Performance

Shares of NASDAQ:IVVD traded up $0.00 during mid-day trading on Monday, reaching $0.70. 757,959 shares of the company traded hands, compared to its average volume of 645,812. The company’s 50 day moving average price is $0.92 and its 200-day moving average price is $1.16. The firm has a market cap of $83.68 million, a PE ratio of -0.36 and a beta of 0.65. Invivyd has a 52 week low of $0.58 and a 52 week high of $5.20.

Analysts Set New Price Targets

A number of brokerages have weighed in on IVVD. HC Wainwright decreased their target price on Invivyd from $15.00 to $10.00 and set a “buy” rating for the company in a research report on Wednesday, November 20th. D. Boral Capital reissued a “buy” rating and issued a $9.00 target price on shares of Invivyd in a research report on Thursday, November 21st. EF Hutton Acquisition Co. I raised Invivyd to a “strong-buy” rating in a research report on Wednesday, October 30th. Finally, Morgan Stanley decreased their target price on Invivyd from $9.50 to $3.55 and set an “overweight” rating for the company in a research report on Wednesday, November 20th. Four research analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, Invivyd presently has an average rating of “Buy” and an average target price of $7.89.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in IVVD. Duquesne Family Office LLC purchased a new stake in Invivyd during the 2nd quarter valued at approximately $629,000. Vanguard Group Inc. grew its holdings in Invivyd by 3.9% during the 1st quarter. Vanguard Group Inc. now owns 2,611,202 shares of the company’s stock valued at $11,594,000 after buying an additional 97,496 shares in the last quarter. Acadian Asset Management LLC grew its holdings in Invivyd by 232.0% during the 2nd quarter. Acadian Asset Management LLC now owns 678,706 shares of the company’s stock valued at $745,000 after buying an additional 474,301 shares in the last quarter. Tidal Investments LLC purchased a new stake in Invivyd during the 1st quarter valued at approximately $126,000. Finally, Cornercap Investment Counsel Inc. purchased a new stake in Invivyd during the 2nd quarter valued at approximately $86,000. 70.36% of the stock is currently owned by institutional investors.

About Invivyd

Invivyd, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering.